kinesin family member 13AGenealiases: RBKIN · bA500C11.2
Q-omics provides the consensus-scored KIF13A profile across patient tissues and cancer cell-line models. KIF13A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIF13A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, KIF13A protein abundance shows 29,252 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, HNSC, and LUAD as cancer lineages where KIF13A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF13A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF13A survival associations across molecular data types. KIF13A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF13A RNA expression–survival associations across cancer types. High KIF13A expression shows unfavorable associations in LIHC and LUSC, but favorable associations in KIRC, UCS, LGG and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIF13A RNA expression.
This table summarizes KIF13A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KIF13A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF13A shows lower tumor expression in THCA, UCEC, BRCA and BLCA and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher KIF13A RNA expression in tumor versus normal tissue (log2 FC = +1.261, t-test p < 0.001).
This table shows molecular features associated with KIF13A in patient tissues and cancer cell lines. In patient samples, KIF13A shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF13A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
